Introduction {#Sec1}
============

Hepatic cysts are fluid-filled cavities in the liver that congenitally arise from aberrant cholangiocytes \[[@CR1]\]. Cysts occur in a spectrum from sporadic lesions to numerous cysts as part of polycystic liver disease (PLD). Due to continuous epithelial cell proliferation and fluid production, cysts grow over time \[[@CR2], [@CR3]\]. Large hepatic cysts lead to invalidating symptoms as pain, nausea and dyspnoea due to mechanical compression of surrounding organs that ultimately compromise the patients' quality of life \[[@CR4]--[@CR6]\].

Aspiration sclerotherapy is a minimally invasive procedure aimed at reducing the volume of these fluid-filled lesions \[[@CR7]\]. Injecting ethanol (or other sclerosing agents) directly in the cyst cavity destroys the inner cyst-lining epithelium \[[@CR8]--[@CR10]\]. Lysis of these epithelial cells halts cell proliferation and cyst fluid production \[[@CR11]\]. Aspiration sclerotherapy generally reaches favourable results in solitary cysts or dominant cysts in PLD \[[@CR7]\]. However, reported long-term efficacy of cyst reduction is mixed and ranges from complete regression to recurrence of the cyst \[[@CR12], [@CR13]\]. An important predictor of cyst reduction is the extent of intracystic fluid reaccumulation after treatment \[[@CR14]\]. Typically, cyst fluid reaccumulates in the first weeks after treatment \[[@CR15]\]. It is hypothesized that this transient fluid production may result from remnants of the cyst wall that are not eliminated by sclerotherapy \[[@CR16]\]. This initial fluid relapse threatens long-term efficacy and may lead to recurrence of the cyst necessitating re-intervention \[[@CR14], [@CR15]\].

Somatostatin analogues inhibit cyst fluid production and cell proliferation by activating somatostatin receptors on the basolateral surface of the cyst \[[@CR3], [@CR17]\]. Previous studies showed that lanreotide and octreotide reduce cystic volume in patients with polycystic liver disease \[[@CR18], [@CR19]\]. Pasireotide (SOM230) is a more potent somatostatin analogue due to a broader binding profile and higher affinity to somatostatin receptor subtypes \[[@CR20]\].

Adjuvant treatment of pasireotide with aspiration sclerotherapy has the promise of curtailing fluid reaccumulation and reducing cholangiocyte proliferation. This strategy has precedence as surgeons have described the use of octreotide after surgical cyst fenestration in an observational study (n = 5) and observed minimized fluid production by exposed remnants of fenestrated cysts leading to apparent control of ascites \[[@CR21]\].

We hypothesized that the combined approach of aspiration sclerotherapy and pasireotide would decrease fluid accumulation and improve long-term cyst reduction and clinical response. Therefore, the purpose of this study was to test whether pasireotide could improve the efficacy of aspiration sclerotherapy of large symptomatic hepatic cysts.

Materials and methods {#Sec2}
=====================

This study was performed following approval by the Institutional Review Board (Medical Research Ethics Committee of the region Arnhem-Nijmegen) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The trial was registered at [ClinicalTrials.gov](http://clinicaltrials.gov) (NCT02048319). We previously reported a detailed protocol elsewhere \[[@CR22]\]; a brief description is given below.

Study design and participants {#Sec3}
-----------------------------

This randomized, single-centre, double-blind, placebo-controlled trial was carried out in the Radboud University Centre, Nijmegen, The Netherlands between April 2014 and April 2016. Trial duration was 26 weeks. Following written informed consent, we randomized patients in a 1:1 ratio to pasireotide or placebo. Randomization was concealed to patients and investigators.

Patients aged between 18 and 70 years with a large (\> 5 cm) symptomatic solitary or dominant hepatic cyst were eligible for participation. A dominant cyst was regarded as the largest cyst within PLD. Major exclusion criteria were: a complicated cyst (neoplastic or hydatid cyst), a prolonged corrected QT-interval (\> 470 ms), symptomatic cholecystolithiasis, uncontrolled diabetes (HbA1C \> 64 mmol/mol) and surgical or radiological cyst interventions within 6 months prior to the study.

Study procedures {#Sec4}
----------------

All patients received aspiration sclerotherapy. In brief, we performed a single-session sclerotherapy procedure. The procedure was performed using conscious sedation with propofol (propofol 10 mg/ml, Fresenius, Bad Homburg vor der Höhe, Germany) and alfentanyl (rapifen, 5 mg/10 ml, Tilburg, The Netherlands). Guided by ultrasound, the interventional radiologist inserted a 5 French pigtail catheter (Cook Medical, Bloomington, IL, USA) in the cyst and performed fluid drainage until collapse of the cyst. Cyst leakage was ruled out by instillation of contrast medium (Iomeron 300, Bracco Imaging, Konstanz, Germany, up to 20 ml) followed by 10-min sclerotherapy. We injected 100 % ethanol in a 10 % ratio of the aspirated cyst volume (up to 50 ml) \[[@CR23]\]. All patients were hospitalized for 24-h observation.

The intervention arm received 60 mg pasireotide (SOM230, Novartis, Basel, Switzerland) long-acting release (LAR). This formulation is injected intramuscularly and secures an extended-release depot suitable for monthly administration \[[@CR20]\]. Based on its pharmacokinetic profile we administered pasireotide 2 weeks before and 2 weeks after aspiration sclerotherapy to reach optimal drug levels around the procedure. Controls received placebo injections of sodium chloride 0.9 % (Fresenius Kabi, Hesse, Germany) at equal time points: 2 weeks before and 2 weeks after aspiration sclerotherapy. Injections were omitted if safety laboratory margins (fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, bilirubin and amylase) were exceeded \[[@CR22]\]. Injections were administered by unblinded healthcare professionals not involved in the design or analysis of this trial.

Study endpoints {#Sec5}
---------------

The primary outcome was the mean proportional change (%) in cyst diameter of the treated hepatic cyst from baseline to week 6, as measured by ultrasonography. Secondary outcomes were change in cyst diameter at 14 and 26 weeks; cyst volume reduction at 6, 14 and 26 weeks; recurrence rate (\< 20 % reduction) at 6 and 26 weeks; patient-reported outcomes (change in symptoms and health-related quality of life) at 6 and 26 weeks; and rate and severity of adverse events during trial participation.

Ultrasonography measurement {#Sec6}
---------------------------

All ultrasound measurements were performed by the primary blinded operator (TW) using a 3.5 MHz convex transducer (Acuson X150^TM^, Siemens Healthcare, Erlangen, Germany). At baseline, the indicated cyst was visualized in two planes to measure the maximal orthogonal diameters, from which we calculated one mean diameter (Supplementary Fig. [1](#MOESM4){ref-type="media"}). In addition, cyst volume was estimated by the ellipsoid volume formula (D1\*D2\*D3\*0.523) \[[@CR15]\]. In case of a dominant cyst, the segmental location and surrounding structures (cysts and vessels) were closely documented to secure identification of the treated cyst at follow-up. Measurements were repeated at weeks 6, 14 and 26 to obtain the proportional (%) change. A second blinded independent operator (ML) repeated all measurements of all patients to assess interobserver variability. In addition, the primary operator repeated measurements in a subset of nine patients to evaluate intra-observer variability.

Patient-reported outcomes {#Sec7}
-------------------------

To evaluate symptoms, patients completed the Polycystic Liver Disease-Questionnaire (PLD-Q), which assesses frequency and discomfort of 13 PLD-related symptoms over a timeframe of one month \[[@CR24]\]. Scores can be compiled to a total sumscore from 1 (asymptomatic) to 100 (severe symptomatic) points. To evaluate health-related quality of life (HRQL) we used the generic Medical Outcomes Study 36-item short-form health survey (SF-36) \[[@CR25]\]. Scores were summarized to a norm-based physical (PCS) and mental component score (MCS), with a general population reference of 50 ± 10 \[[@CR26]\]. Lower PCS or MCS scores indicate a compromised HRQL \[[@CR27]\].

Statistical analysis {#Sec8}
--------------------

Based on data from a previous cohort \[[@CR28]\], we expected 30 % cyst diameter reduction 4 weeks after aspiration sclerotherapy. We hypothesized that this reduction at 4 weeks would be improved to 50 % by adjuvant treatment with pasireotide. In order to detect a statistical difference between groups, we needed a sample size of 34 participants (power: 80 %; α: 0.05; drop-out rate: 10 %). Intention-to-treat analysis was performed including all patients who received at least one dose of pasireotide. In addition, a parallel per-protocol analysis was conducted in patients who received both injections and aspiration sclerotherapy. Values were reported as median with interquartile range. For continuous endpoints, we calculated differences between arms using the Mann-Whitney U test. To correct for baseline diameter differences and underlying diagnosis (solitary cyst or PLD) between arms, we performed a sensitivity analysis using ANCOVA. The Wilcoxon signed-rank test was used to compare within-group differences. Cyst recurrence was compared between groups by Fisher's exact test. In case of a missing variable, we carried the last available value forward. Summarizing scores of patient-reported outcomes (PLD-Q sumscore, PCS, MCS) were compared between groups after treatment. To assess safety, we compiled frequency tables for adverse events classified according to WHO adverse reaction terminology. Statistical analyses were performed prior to unblinding using SPSS (version 22.0; SPSS, Chicago, IL, USA). Analyses were two-sided with a *p*-value \< 0.05 considered statistically significant.

Results {#Sec9}
=======

Baseline characteristics {#Sec10}
------------------------

We screened 71 consecutive patients with symptomatic hepatic cysts for eligibility. Of these, 28 patients did not meet the inclusion criteria and nine patients declined to participate (Fig. [1](#Fig1){ref-type="fig"}). In total, 34 participants (female n = 32, male n = 2) were randomly assigned to either pasireotide or placebo. Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow diagram. *ITT* intention-to-treat, *PP* per-protocolTable 1Demographics and baseline characteristicsPasireotide (n = 17)Placebo (n = 17)Age at treatment, years54 \[51--61\]50 \[45--61\]Female sex, n16 (94)16 (94)PLD (\>20 cysts), n10 (59)13 (76)Baseline cyst diameter, cm10.4 \[8.2--13.4\]9.0 \[7.1--10.8\]Baseline cyst volume, ml529.8 \[288.4--1027.1\]378.2 \[188.5--635.7\]BMI, kg/m^2^27.3 \[25.1--30.2\]23.2 \[22.2--27.4\]Continuous data are reported as median \[interquartile range\], absolute numbers as n (%)*PLD* polycystic liver disease, *BMI* body mass index

All subjects were included in the intention-to-treat analysis. One aspiration sclerotherapy procedure failed as the targeted cyst could not be punctured due to a deep cranial position. This patient did not receive a second injection. In both groups one patient did not receive a second injection due to adverse events (hyperglycaemia and dizziness). Finally, one patient (pasireotide-arm) had a second aspiration sclerotherapy procedure at week 24 due to ongoing severe complaints. From another patient (placebo-arm), the treated cyst could not be identified from other cysts at week 26. Findings at week 14 of these two patients were carried forward to week 26 for analysis.

Primary outcome {#Sec11}
---------------

### Intention-to-treat analysis {#Sec12}

Median cyst diameter in the pasireotide-arm decreased by 23.6 % (interquartile range \[IQR\] 12.6--30.0) compared to 21.8 % (IQR 9.6--31.8) in patients assigned to placebo (Fig. [2](#Fig2){ref-type="fig"}). Proportional diameter reduction was similar (*p* = 0.96) between groups. When corrected for baseline diameter and diagnosis by ANCOVA, proportional reduction remained equal (*p* = 0.64).Fig. 2Primary outcome. Diameter reduction compared to baseline at week 6

### Per-protocol analysis {#Sec13}

The three patients who did not receive a second injection were excluded from per-protocol analysis, resulting in a sample of 31 patients (Fig. [1](#Fig1){ref-type="fig"}). In the pasireotide-sample (n = 15), cyst diameter reduced by 23.6 % (IQR 15.8--32.0) compared to 22.6 % (IQR 12.4--32.4) in patients receiving placebo (n = 16). Similar to the intention-to-treat analysis, we found no statistical significant difference between groups (*p* = 0.83).

### Intra- and interobserver variability {#Sec14}

We found a mean difference of 0.45 % ± 2.72 % between measurements of the primary operator with an intraclass coefficient of r = 0.99 (*p* \< 0.01). Compared to measurements of the second operator there was a mean difference of 1.75 % ± 5.30 %, with an intraclass coefficient of r = 0.97 (*p* \< 0.01).

Secondary outcomes {#Sec15}
------------------

### Long-term cyst diameter reduction {#Sec16}

The two groups showed similar progressive long-term diameter reduction (Fig. [3](#Fig3){ref-type="fig"}). At week 14, median proportional cyst diameter reduction was 37.5 % (IQR 24.0--52.6) in patients assigned to pasireotide and 30.3 % (IQR 19.5--48.4) in controls (*p* = 0.84). At week 26, treated cyst diameters had further reduced to 49.1 % (IQR 27.0--73.6) (pasireotide) and 45.6 % (IQR 29.6--59.6) (placebo) compared to baseline (*p* = 0.90; Supplementary Table [1](#MOESM1){ref-type="media"}).Fig. 3Cyst diameter (**A**) and volume (**B**) reduction from baseline to weeks 6, 14 and 26 compared between pasireotide and placebo

### Volume reduction and cyst recurrence {#Sec17}

Changes in volume from baseline to 26 weeks are shown in Fig. [3](#Fig3){ref-type="fig"}. Similar to diameter results, groups achieved comparable volume reduction rates (Supplementary Table [2](#MOESM2){ref-type="media"}). In both groups, 8/17 (47 %) patients showed cyst recurrence at week 6. This decreased to one patient in the pasireotide group and two patients in the placebo group at the end of the trial (*p* = 0.6).

Patient-reported outcomes {#Sec18}
=========================

Total PLD-Q score showed a statistically significant (*p* \< 0.01) decrease over time in both groups indicating symptomatic improvement (Fig. [4](#Fig4){ref-type="fig"}). Final PLD-Q improvement was comparable between groups (*p* = 0.95; Supplementary Table [3](#MOESM3){ref-type="media"}). At baseline, the physical domain of HRQL was restricted at baseline in both arms. After treatment, PCS improved in both groups with a statistically significant effect in the pasireotide sample (*p* \< 0.01). Nonetheless, PCS at week 26 was similar among arms (*p* = 0.43). Baseline MCS was slightly restricted in the pasireotide group and normal in controls. In both groups the MCS increased; however, the final MCS was similar (*p* = 0.56).Fig. 4Symptomatic improvement from baseline to week 26 (T26), assessed by the disease-specific Polycystic Liver Disease Questionnaire (PLD-Q) leading to a summarizing score. The dotted line (reference) indicates the general population score

Adverse events {#Sec19}
--------------

There were four serious adverse events requiring hospital admission. One female patient developed a cyst-bleeding 10 days after aspiration sclerotherapy that was treated with analgesics. A male patient developed urolithiasis that was treated surgically. Furthermore, a female patient developed pneumonia, which was treated with antibiotics and analgesics. Finally, a female patient underwent a second aspiration sclerotherapy of the treated cyst due to ongoing severe abdominal distension and inadequate cyst reduction from the first procedure.

The most common adverse event was abdominal pain (pasireotide n = 13; placebo n = 11), which was mild and self-limiting in 20 cases (Table [2](#Tab2){ref-type="table"}). In the remaining four cases, pain was more severe (grade III) and analgesics were needed to relieve symptoms. Glucose levels in the pasireotide group rose from 5.3 mmol/L (IQR 5.1--6.1 mmol/L) to 6.8 mmol/L (IQR 6.6--7.7 mmol/L) at week 4 (*p* \< 0.01) and normalized at the end of follow-up. By contrast, median levels in patients on placebo did not differ over time (Supplementary Fig. [2](#MOESM5){ref-type="media"}).Table 2Adverse eventsPasireotide (n = 17)Placebo (n = 17)TotalGrade 3TotalGrade 3Hyperglycaemia17 (100)05 (29)0Abdominal pain13 (76)1 (6)11 (65)3 (18)Loose stools13 (76)010 (58)0Fatigue10 (58)07 (41)0Nausea8 (47)06 (35)0Skin response injection site6 (35)01 (6)0Palpitations4 (24)01 (6)0Vomiting3 (18)01 (6)0Decreased satiety3 (18)01 (6)0Overall malaise3 (18)01 (6)0Menstruation disorders^1^2 (13)000Dizziness2 (12)02 (12)0Thrombotic events^2^2 (12)100Pneumoniae/pneumonitis1 (6)01 (6)1 (6)Urolithiasis1 (6)1 (6)00Serious adverse events^3^2 (12)2 (12)Values are given as number (percent)^1^Prolonged period (n = 1); irregular menstruation (n = 1)^2^Thrombosis vena subclavia after peripheral catheter left arm (n = 1); superficial thrombosis lower right leg (n = 1)^3^Serious adverse events: cyst bleeding (n = 1); urolithiasis (n = 1); re-intervention hepatic cyst (n = 1); pneumonia (n = 1)

Discussion {#Sec20}
==========

The key finding of this study is that a pre- and postprocedural intramuscular injection of pasireotide LAR in addition to aspiration sclerotherapy does not improve cyst reduction or clinical outcomes compared to controls. In both arms, we found symptomatic relief and normalized HRQL, underlining the clinical benefit that can be achieved by aspiration sclerotherapy.

We expected that a combined approach to target cysts, i.e. pasireotide and aspiration sclerotherapy, would enhance efficacy over mere aspiration sclerotherapy. This hypothesis was based upon the working mechanism of somatostatin analogues. Somatostatin analogues lower intracellular levels of 3'-5'-cyclic adenosine monophosphate (cAMP) by binding somatostatin receptors (SSTR) \[[@CR3], [@CR17]\]. This second messenger cAMP stimulates cyst fluid production by activating chloride (cystic fibrosis transmembrane conductance regulator; CFTR) and water (aquaporin 1) channels on the apical side of the cyst epithelial cells \[[@CR29]\]. In addition, cAMP stimulates cell hyperproliferation leading to cyst growth \[[@CR30], [@CR31]\]. Therefore, by lowering intracellular levels of cAMP, cyst fluid production is curtailed and epithelial cell proliferation suppressed, collectively leading to cyst regression \[[@CR17], [@CR31]\]. Previous clinical studies showed how somatostatin analogues reduce polycystic liver volume \[[@CR18]\]. We expected that these features would reduce post-intervention fluid reaccumulation and improve long-term cyst reduction.

Nonetheless, we found no differences between groups. Our efficacy results were comparable with other studies that performed mere aspiration sclerotherapy \[[@CR7]\]. Why was our hypothesis not recapitulated by the results of our study? First, while other somatostatin analogues such as lanreotide and octreotide decrease hepatic cyst volumes, it is possible that pasireotide does not inhibit hepatic cystogenesis in humans. Compared to conventional somatostatin analogues, pasireotide has a broader binding profile (octreotide SSTR ~2,\ 3,~ and SSTR~5~; pasireotide SSTR ~1,2,3,~ and SSTR~5~) and a higher affinity to SSTR ~1,\ 3~ and SSTR~5~ \[[@CR20]\]. Based on this pharmacological profile, it is reasonable to assume that pasireotide also reduces cyst progression in humans. However, no human studies have reported the effects of pasireotide on hepatic cysts. Currently, a randomized clinical trial is being conducted to investigate the efficacy of pasireotide in polycystic liver disease, which will provide better insight into the cyst-reducing properties of pasireotide ([Clinicaltrials.gov](http://clinicaltrials.gov); NCT01670110).

In addition, we may have administrated pasireotide in an inadequate dosage or regimen to be effective. In order to optimize the efficacy/safety balance we targeted our patients with pasireotide in a limited period before and after the procedure. To reach optimal drug levels, we administered a dosage of 60 mg in a long-acting release formulation. This is the highest available dosage within the safety range \[[@CR32], [@CR33]\]. The mild hyperglycaemia that followed pasireotide injections suggests adequate exposure to the drug.

Finally, the process of post-procedural cyst fluid reaccumulation leading to recurrence may not be affected by pasireotide. Alternatively, it is hypothesized that fluid reaccumulation results from an inflammatory response induced by cell lysis following sclerotherapy, rather than fluid production of remaining functional cyst epithelium \[[@CR13]\]. An exploratory study repunctured treated cysts 2--8 days following aspiration sclerotherapy and observed an increase in leukocytes compared to the primary aspirate, suggesting ongoing inflammation \[[@CR34]\].

Traditionally, efficacy studies of aspiration sclerotherapy focused on the technical (morphological) response of aspiration sclerotherapy \[[@CR5], [@CR7]\]. As hepatic cysts are benign lesions, indication for treatment is driven upon the patient's symptomatology. This was the first study to assess patient-reported outcomes at standardized time points using validated instruments. At baseline, we found low physical SF-36 scores and increased PLD-Q scores indicating a restricted HRQL a symptomatic burden compared to general population references \[[@CR26]\]. In this study we demonstrated that aspiration sclerotherapy significantly reduces disease-specific symptoms and normalizes HRQL. These findings support the notion that aspiration sclerotherapy is an excellent first-line choice to treat patients with large symptomatic hepatic cysts.

The strength of this study is that we combined an invasive and medical strategy to optimize cyst reduction in a clinical trial design. This study also has several limitations. Firstly, our primary endpoint was measured by ultrasonography, which introduces variability as it is operator-dependent. CT or MRI may reduce variability, but would have led to unnecessary exposure to radiation and/or costs as this study required multiple measurements within short intervals. To minimize bias, all measurements were performed by the same investigator following standardized operating procedures. As a result, we found excellent intraclass coefficients of intra- and interobserver variability \[[@CR35]\]. Secondly, we powered our study assuming a large beneficial effect from pasireotide. Possible smaller differences between our groups cannot be ruled out. However, we believe that such small differences would not be relevant for clinical practice, given the costs of pasireotide. Finally, we included both sporadic hepatic cysts and dominant hepatic cysts within PLD. The genetic background of both congenital cyst types corresponds as somatic loss of PLD-type alleles from cyst epithelium is required to drive cyst formation \[[@CR36]\]. Indeed, both cyst types have a thin wall lined by a single layer of aberrant cholangiocytes, which are targetable by somatostatin analogues \[[@CR4], [@CR37]\]. However, it is unclear if germline mutations in PLD patients alter susceptibility to these agents. In our study, we found no differences in efficacy between patients with or without underlying PLD, as reflected in the previous literature \[[@CR8]\].

In summary, adjuvant pasireotide treatment to aspiration sclerotherapy in patients with large hepatic cysts is no more effective than aspiration sclerotherapy alone. Aspiration sclerotherapy normalizes HRQL-rates and decreases symptomatic disease, which proves aspiration sclerotherapy is an excellent choice of therapy for large hepatic cysts.
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